Results 31 to 40 of about 67,411 (205)

Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients

Saudi Pharmaceutical Journal, 2022
Background: Capecitabine is one of the fluoropyrimidine anticancer agents which is extensively used in the management of colorectal cancer. We have noticed a discrepancy between the doses we are using in our patients and the recommended dosing regimen ...
Saeed Alqahtani, Rawan Alzaidi, Abdullah Alsultan, Abdulaziz Asiri, Yousif Asiri, Khalid Alsaleh   +5 more
doaj   +1 more source

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

New England Journal of Medicine, 2019
BACKGROUND Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral,
R. Murthy, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S. Hurvitz, N. Lin, V. Borges, V. Abramson, C. Anders, P. Bedard, Mafalda Oliveira, E. Jakobsen, T. Bachelot, S. S. Shachar, V. Müller, S. Braga, F. Duhoux, R. Greil, D. Cameron, L. Carey, G. Curigliano, K. Gelmon, G. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, M. C. Palanca-Wessels, L. Walker, W. Feng, E. Winer   +31 more
semanticscholar   +1 more source

Capecitabine-Associated Terminal Ileitis

Case Reports in Oncology, 2018
Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents.
Irene E.G. van Hellemond, Annemarie M. Thijs, Geert-Jan Creemers   +2 more
doaj   +1 more source

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

The Lancet, 2017
BACKGROUND The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer.
J. Neoptolemos, D. Palmer, P. Ghaneh, E. Psarelli, J. Valle, C. Halloran, O. Faluyi, D. O’reilly, D. Cunningham, J. Wadsley, S. Darby, T. Meyer, R. Gillmore, A. Anthoney, P. Lind, B. Glimelius, S. Falk, J. Izbicki, G. Middleton, S. Cummins, P. Ross, H. Wasan, A. Mcdonald, T. Crosby, Yuk Ting Ma, K. Patel, David Sherriff, R. Soomal, D. Borg, S. Sothi, P. Hammel, T. Hackert, R. Jackson, M. Büchler   +33 more
semanticscholar   +1 more source

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

JAMA Oncology, 2022
This multicenter, open-label randomized clinical trial conducted in China compares the efficacy and safety of adjuvant capecitabine with concurrent chemoradiotherapy vs concurrent chemoradiotherapy alone for treatment of patients with locoregionally ...
J. Miao, Lin Wang, S. Tan, Jingao Li, J. Yi, E. Ong, L. Y. Tan, Ye Zhang, X. Gong, Qiu-Yan Chen, Yan-Qun Xiang, Ming-Yuan Chen, Ying Guo, X. Lv, W. Xia, Linquan Tang, Xiaowu Deng, Xiang Guo, F. Han, H. Mai, M. Chua, Chong Zhao   +21 more
semanticscholar   +1 more source

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

The Lancet Oncology, 2019
BACKGROUND Despite improvements in multidisciplinary management, patients with biliary tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection with curative intent, with 5-year overall survival of less than 10% for all ...
J. Primrose, R. Fox, D. Palmer, H. Malik, R. Prasad, D. Mirza, A. Anthony, P. Corrie, S. Falk, M. Finch-Jones, H. Wasan, P. Ross, L. Wall, J. Wadsley, J. Evans, D. Stocken, R. Praseedom, Yuk Ting Ma, B. Davidson, J. Neoptolemos, T. Iveson, J. Raftery, Shihua Zhu, D. Cunningham, O. Garden, C. Stubbs, J. Valle, J. Bridgewater   +27 more
semanticscholar   +1 more source

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Journal of Clinical Oncology, 2021
PURPOSE Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine.
I. Mayer, Fengmin Zhao, C. Arteaga, W. Symmans, B. Park, B. Burnette, Amye J. Tevaarwerk, S. Garcia, K. Smith, D. Makower, M. Block, Kimberly A Morley, C. R. Jani, C. Mescher, S. J. Dewani, B. Tawfik, L. Flaum, E. Mayer, W. Sikov, E. Rodler, L. Wagner, A. DeMichele, J. Sparano, A. Wolff, K. Miller   +24 more
semanticscholar   +1 more source

Effect of capecitabine on breast cancer patients with different estrogen receptor status

Bangladesh Journal of Pharmacology, 2020
This meta-analysis is to compare the efficacy of capecitabine versus non-capecitabine chemotherapy on breast cancer patients with different estrogen receptor (ER) status.
Gang Xu, Xin Lv, Ke Lu, Ming Hai Shen, Qing Hua Zhang, Wan Neng Pan   +5 more
doaj   +1 more source

Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer

Cancer Treatment and Research Communications, 2023
Background: The combination of endocrine treatment with cycline-dependent-kinase 4/6 inhibitor is the new standard of treatment in hormone receptor-positive HER2 negative metastatic breast cancer.
L. Bender, C. Pflumio, P. Trensz, L. Pierard, M. Kalish, C. Fischbach, T. Petit   +6 more
doaj   +1 more source

Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?

Oncology Reviews, 2011
Fluorouracil (5-FU) remains the most widely used agent for colorectal cancer. Capecitabine is a rationally designed 5-FU pro-drug developed to mimic the continuous infusion of 5-FU while avoiding complications and inconvenience of intravenous ...
Lakshmi Chintala, Susmitha Vaka, Joaquina Baranda, Stephen K. Williamson   +3 more
doaj   +1 more source